Zai Lab Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Zai Lab kazanç ve gelirin sırasıyla yıllık 65.4% ve 33.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 63.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -22.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

65.4%

Kazanç büyüme oranı

63.6%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.3%
Gelir büyüme oranı	33.1%
Gelecekteki özkaynak getirisi	-22.3%
Analist kapsamı	Good
Son güncelleme	25 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Sep 28

Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

Sep 23

Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why

Jun 12

Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified

May 14

A Risky Bet: Zai Lab's Uncertain Future

Apr 16

Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

Mar 29

We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Mar 24

Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Jan 18

Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Sep 22

Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 24

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:ZLAB - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	925	68	40	181	12
12/31/2025	582	-178	-199	-150	15
12/31/2024	393	-294	-318	-269	15
6/30/2024	323	-298	-215	-202	N/A
3/31/2024	291	-339	-223	-219	N/A
12/31/2023	267	-335	-193	-198	N/A
9/30/2023	263	-301	-291	-293	N/A
6/30/2023	252	-393	-371	-364	N/A
3/31/2023	231	-410	-368	-350	N/A
12/31/2022	215	-443	-393	-368	N/A
9/30/2022	197	-593	-438	-411	N/A
6/30/2022	182	-529	-472	-446	N/A
3/31/2022	171	-554	-494	-467	N/A
12/31/2021	144	-704	-568	-549	N/A
9/30/2021	115	-569	-458	-441	N/A
6/30/2021	87	-537	-374	-359	N/A
3/31/2021	61	-454	-357	-346	N/A
12/31/2020	49	-269	-227	-216	N/A
9/30/2020	39	-239	-219	-212	N/A
6/30/2020	29	-240	-212	-200	N/A
3/31/2020	19	-201	-203	-189	N/A
12/31/2019	13	-195	-206	-191	N/A
9/30/2019	8	-212	-209	-196	N/A
6/30/2019	4	-181	N/A	N/A	N/A
3/31/2019	2	-160	N/A	N/A	N/A
12/31/2018	0	-139	-108	-98	N/A
9/30/2018	N/A	-89	N/A	N/A	N/A
6/30/2018	N/A	-67	N/A	N/A	N/A
3/31/2018	N/A	-59	N/A	N/A	N/A
12/31/2017	N/A	-50	N/A	-32	N/A
9/30/2017	N/A	-50	N/A	N/A	N/A
6/30/2017	N/A	-50	N/A	-41	N/A
3/31/2017	N/A	-44	N/A	-37	N/A
12/31/2016	N/A	-38	N/A	-32	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ZLAB önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: ZLAB önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: ZLAB önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: ZLAB şirketinin gelirinin (yıllık 33.1% ) US pazarından (yıllık 8.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ZLAB şirketinin gelirinin (yıllık 33.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ZLAB 3 yıl içinde kârsız olması bekleniyor.

Zai Lab Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus estimates of losses per share improve by 16%

Forecast to breakeven in 2026

Price target decreased by 11% to US$56.44

Consensus EPS estimates upgraded to US$3.45 loss, revenue downgraded

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Recent updates

Zai Lab Limited Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

Zai Lab Limited Presents Data from the Ongoing Global Phase 1A/1B Study of ZL-1310

Zai Lab Limited to Report Q3, 2024 Results on Nov 12, 2024

Zai Lab Limited to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024

Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

Zai Lab Limited to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024

Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Zai Lab Limited to Report Q2, 2024 Results on Aug 06, 2024

Zai Lab Limited Announces Executive Changes, Effective June 30, 2024

Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why

Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Insider notifies of intention to sell stock

Consensus estimates of losses per share improve by 16%

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified

Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA

First quarter 2024 earnings released: US$0.55 loss per share (vs US$0.51 loss in 1Q 2023)

Forecast to breakeven in 2026

A Risky Bet: Zai Lab's Uncertain Future

Zai Lab Limited to Report Q1, 2024 Results on May 08, 2024

Zai Lab Limited, Annual General Meeting, Jun 18, 2024

Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Zai Lab Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Price target decreased by 11% to US$56.44

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Zai Lab Limited to Report Fiscal Year 2023 Results on Feb 27, 2024

Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Zai Lab Announces the New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

Key Executive notifies of intention to sell stock

Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List

Consensus EPS estimates upgraded to US$3.45 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zai Lab Limited to Report Q3, 2023 Results on Nov 07, 2023

Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Zai Lab Limited Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with Ntrk-Positive Tki-Pretreated Advanced Solid Tumors in China

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Zai Lab Limited to Report Q2, 2023 Results on Aug 07, 2023

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis

New minor risk - Profitability

Zai Lab Limited Announces Chief Financial Officer Changes, Effective July 7, 2023

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Insider exercised options to buy US$295k worth of stock.

Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

New minor risk - Share price stability

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Zai Lab Limited to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting

We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Zai Lab Limited Announces China’s National Medical Products Administration Grants Priority Review to Repotrectinib

Consensus EPS estimates upgraded to US$3.21 loss

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Founder exercised options to buy US$292k worth of stock.

Forecast to breakeven in 2025

Insider exercised options and sold US$425k worth of stock

Full year 2022 earnings released: US$4.62 loss per share (vs US$7.58 loss in FY 2021)

Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?

Zai Lab Limited to Report Fiscal Year 2022 Results on Mar 01, 2023

Zai Lab Limited Announces New Drug Application for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s National Medical Products Administration

Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans

Zai Lab Limited Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

Zai Lab Limited Appoints Michel Vounatsos to the Board of Directors

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint